Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
LOGOS is a generative AI strategy that designs binding proteins for peptides and intrinsically disordered protein regions by combining prefabricated binding-pocket parts. Chemistry World reported that the approach produced tight binders for 39 of 43 tested targets. Those results point to a new protein-design route—not to medicines already shown to treat pain or cancer in people.
Why are some proteins called “undruggable”?
Here, “undruggable” is shorthand for a design challenge, not a claim that no drug can ever affect these targets. Intrinsically disordered regions do not settle into one stable, pocket-like shape. That makes conventional structure-guided small-molecule design difficult: there may be no fixed pocket for a molecule to fit.
LOGOS takes a different tack. It aims to create a protein binder that recognizes a disordered region or peptide, rather than relying on a small molecule fitting a stable pocket. The approach was inspired by designed ankyrin repeat proteins (DARPins), engineered repeat-protein scaffolds used as binders.
How does the LOGOS design strategy work?
Instead of designing a binder as one uninterrupted structure, LOGOS assembles it from prefabricated binding-pocket parts. Chemistry World describes a library of 1,000 parts and trillions of possible combinations. The strategy uses generative AI to mix and match those components into candidate binders for a target.
#1 Best Overall
This modular design is intended to address the flexible nature of disordered targets. It is distinct from screening a large physical library to find a binder; co-lead author Kejia Wu said she was interested in whether a system could work for fully disordered regions “without the tedious library screening.”
What did the reported experiments find?
Chemistry World’s 29 July 2025 report on the study by K. Wu and colleagues in Science says the team tested 43 targets and obtained tight binders for 39. The report does not provide the definition of “tight binder” or target-by-target data, so the figure should be read as the reported outcome rather than an independently checked success rate.
Dynorphin and pain pathways
One designed binder targeted dynorphin, an opioid peptide. In cultured human cells, the binder reportedly blocked pain pathways. This is a cell-culture result; it does not show that the binder relieves pain in people or is a treatment.
Signalling and cell-surface targets
The team also designed binders for three signalling proteins linked to cancer. In addition, the report describes targeting and fluorescent tagging of a cell-surface protein linked to cancer. These experiments demonstrate research uses for the binders, not cancer diagnosis or therapy in clinical practice.
Rank #3
What remains uncertain?
How well does it handle longer disordered regions?
David Baker acknowledged a limitation involving the length of disordered region the method can target. The report does not establish a general maximum length or show how performance changes across longer targets, so the reported results should not be taken as proof that LOGOS works equally well for every disordered protein.
Can it distinguish similar targets?
Birte Höcker, who heads a protein-design lab at the University of Bayreuth, said that specificity and discrimination between very similar targets had not been fully explored. She also wanted more detail on what determines specificity and on binding pockets for peptide side chains. A binder that attaches to its intended target is not necessarily selective enough to avoid binding related molecules.
Rank #4
How representative were the tested targets?
Pranam Chatterjee of the University of Pennsylvania noted that the targets were mostly short peptides, 8–40 residues long, with an inherent tendency to adopt structure, rather than fully disordered proteins. That criticism raises a useful distinction: success on short peptides does not by itself establish equivalent performance on long, flexible regions within intact proteins.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What could LOGOS be used for?
The reported work suggests possible future applications in research, diagnostics, and therapeutics. Designed binders could help detect or label targets, or potentially interfere with a biological pathway. But the evidence described so far is experimental, including cultured-cell work; it does not establish a treatment benefit in people, an available diagnostic, or a medicine ready for use.
The study was reported by Chemistry World on 29 July 2025, which cites K. Wu et al., Science (2025), DOI 10.1126/science.adr8063. Chemistry World is the source for the method, numerical results, and reported limitations summarized here.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
